SCHEMBL24673382

SCHEMBL24673382

CCCCC(CCCC)CN1CC2(CCN(C(=O)C(CCCC)CCCC)CC2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.39
TSHR P16473 3/20 0.38
LMNA P02545 1/20 0.37
USP2 O75604 3/20 0.37
CYP1A2 P05177 2/20 0.37
HIF1A Q16665 2/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CHRM2 P08172 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CHRM1 P11229 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
OPRM1 P35372 1/20 0.37
DRD3 P35462 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25829570 0.97 CYP2D6 (0.38) CYP2D6TSHRLMNAUSP2CYP1A2
SCHEMBL26405347 0.97 CYP2D6 (0.38) CYP2D6TSHRLMNAUSP2CYP1A2
SCHEMBL25707614 0.96 OPRL1 (0.38) CYP2D6TSHRLMNAUSP2CYP1A2
SCHEMBL23945292 0.96 OPRL1 (0.38) CYP2D6TSHRLMNAUSP2CYP1A2
SCHEMBL25728789 0.95 CYP2D6 (0.36) CYP2D6TSHRLMNAUSP2CYP1A2
SCHEMBL25480257 0.95 CYP2D6 (0.38) CYP2D6TSHRLMNAUSP2CYP1A2
SCHEMBL25109469 0.95 CYP2D6 (0.38) CYP2D6TSHRLMNAUSP2CYP1A2
SCHEMBL25884453 0.95 CYP2D6 (0.38) CYP2D6TSHRLMNAUSP2CYP1A2
SCHEMBL23696029 0.87 OPRL1 (0.42) CYP2D6TSHRLMNAUSP2CYP2C9
SCHEMBL25928265 0.87 OPRL1 (0.42) CYP2D6TSHRLMNAUSP2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP2D6 3599/4885TSHR 3319/4885LMNA 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.